1-Apr-2026 6:00 AM CST - Business Wire Novocure to Report First Quarter 2026 Financial Results Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the companys financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To acces
12-Jan-2026 6:00 AM CST - Business Wire Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on th
22-Dec-2025 6:00 AM CST - Business Wire Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief Executive Officer, will present on behalf of the company and address questions on Wednesday, January 14, at 9:45 a.m. PST. Mr. Leonard will be joined by William Doyle, Executive Chairman, and Christoph Brackmann, Chief Financial Officer, for one-on-one meetings
26-Nov-2025 6:00 AM CST - Business Wire Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocures Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocures website, www.novocure.c
12-Nov-2025 6:00 AM CST - Business Wire Novocure to Participate in 2025 Jefferies Global Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be acc
30-Oct-2025 6:00 AM CST - Business Wire Novocure Reports Third Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic expansion, and material progress for our clinical and product de
1-Oct-2025 6:00 AM CST - Business Wire Novocure to Report Third Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the companys financial results for the three- and nine-month periods that ended September 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be
28-Aug-2025 6:00 AM CST - Business Wire Novocure Announces Upcoming Investor Events Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. H.C. Wainwright 27th Annual Global Investment Conference, September 9, 2025: Ms. Cordova will take part in a fireside chat at 2:00 p.m.
24-Jul-2025 6:00 AM CST - Business Wire Novocure Reports Second Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). With the first half of 2025 complete, I am pleased to report continued progress towards our clinical, regulatory and commercial milestones. In Q2, we gr
1-Apr-2026 6:00 AM CST - Business Wire Novocure to Report First Quarter 2026 Financial Results Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the companys financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To acces
12-Jan-2026 6:00 AM CST - Business Wire Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on th
22-Dec-2025 6:00 AM CST - Business Wire Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief Executive Officer, will present on behalf of the company and address questions on Wednesday, January 14, at 9:45 a.m. PST. Mr. Leonard will be joined by William Doyle, Executive Chairman, and Christoph Brackmann, Chief Financial Officer, for one-on-one meetings
26-Nov-2025 6:00 AM CST - Business Wire Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocures Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocures website, www.novocure.c
12-Nov-2025 6:00 AM CST - Business Wire Novocure to Participate in 2025 Jefferies Global Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be acc
30-Oct-2025 6:00 AM CST - Business Wire Novocure Reports Third Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic expansion, and material progress for our clinical and product de
1-Oct-2025 6:00 AM CST - Business Wire Novocure to Report Third Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the companys financial results for the three- and nine-month periods that ended September 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be
28-Aug-2025 6:00 AM CST - Business Wire Novocure Announces Upcoming Investor Events Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. H.C. Wainwright 27th Annual Global Investment Conference, September 9, 2025: Ms. Cordova will take part in a fireside chat at 2:00 p.m.
24-Jul-2025 6:00 AM CST - Business Wire Novocure Reports Second Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). With the first half of 2025 complete, I am pleased to report continued progress towards our clinical, regulatory and commercial milestones. In Q2, we gr
